Twenty-five years clinical trials of the German Hodgkin Study Group (GHSG)

被引：16

作者：

Behringer, K ^{[1
]}

Diehl, V ^{[1
]}

机构：

[1] Univ Hosp Cologne, Dept Internal Med 1, D-50924 Cologne, Germany

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2005年 / 75卷

关键词：

German Hodgkin Study Group; GHSG; review; Hodgkin's Lymphoma; chemotherapy; radiotherapy;

D O I：

10.1111/j.1600-0609.2005.00450.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This review presents a short overview of 25-years of clinical trials by the GHSG for the treatment of primary Hodgkin's Lymphoma. The trials HD1-HD12 that have been conducted between 1978-2002 are reviewed and major results are discussed. Furthermore, the development of the strategies concerning chemo- and radiotherapy for the treatment of Hodgkin's Lymphoma is characterized.

引用

页码：21 / 25

页数：5

共 13 条

[1] Diehl V, 2003, BLOOD, V102, p27A
[2] BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease
Diehl, V
Sieber, M
Ruffer, U
Lathan, B
Hasenclever, D
Pfreundschuh, M
Loeffler, M
Lieberz, D
Koch, P
Adler, M
Tesch, H
[J]. ANNALS OF ONCOLOGY, 1997, 8 (02) : 143 - 148
[3] DIEHL V, 1989, MED ONCOL TUMOR PHAR, V6, P155
[4] Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease
Diehl, V
Franklin, J
Pfreundschuh, M
Lathan, B
Paulus, U
Hasenclever, D
Tesch, H
Herrmann, R
Dörken, B
Müller-Hermelink, H
Dühmke, E
Loeffler, M
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) : 2386 - 2395
[5] DIEHL V, 2004, BLOOD, V104, pA307
[6] DIEHL V, 2004, BLOOD, V104, pA1308
[7] Dühmke E, 2001, J CLIN ONCOL, V19, P2905
[8] Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma:: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group
Engert, A
Schiller, P
Josting, A
Herrmann, R
Koch, P
Sieber, M
Boissevain, F
de Wit, M
Mezger, J
Dühmke, E
Willich, N
Müller, RP
Schmidt, BF
Renner, H
Müller-Hermelink, HK
Pfistner, B
Wolf, J
Hasenclever, D
Löffler, M
Diehl, V
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (19) : 3601 - 3608
[9] GOLDIE JH, 1979, CANCER TREAT REP, V63, P1727
[10] Hasenclever D, 1996, ANN ONCOL, V7, P95

← 1 2 →